SANOFI-AVENTIS (EPA:SAN) Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Transparency directive : regulatory news
20/09/2024 11:30
source : webdisclosure.com
SANOFI-AVENTIS's latest news
17/12/2024 13:30
17/12/2024 07:30
13/12/2024 07:00
11/12/2024 07:00
09/12/2024 20:06
07/12/2024 17:30
06/12/2024 07:30
25/10/2024 07:30
24/10/2024 14:00
21/10/2024 07:30
Other stories
15/01/2025 01:34
15/01/2025 08:04
15/01/2025 07:05
14/01/2025 23:24
15/01/2025 03:51
14/01/2025 05:42
15/01/2025 07:07
14/01/2025 20:04
15/01/2025 09:01
15/01/2025 05:22
15/01/2025 09:00
15/01/2025 07:31
15/01/2025 08:33
14/01/2025 21:01
15/01/2025 08:00
15/01/2025 05:29
14/01/2025 18:45
15/01/2025 08:25
15/01/2025 01:17
14/01/2025 17:30
14/01/2025 20:12
15/01/2025 07:11
14/01/2025 16:56
15/01/2025 08:01
15/01/2025 07:00
14/01/2025 23:45
15/01/2025 08:07
15/01/2025 08:44
15/01/2025 08:59
15/01/2025 02:55
15/01/2025 07:38
14/01/2025 16:57
14/01/2025 10:24
14/01/2025 08:36
15/01/2025 00:32
14/01/2025 18:32
13/01/2025 15:59
15/01/2025 06:01